Concord Medical Services Holdings (FRA:C2C) ROCE %: -5.56% (As of Dec. 2025)


FRA:C2C Concord Medical Services Holdings Ltd FRA:C2C
51 GF Score
Price €6.25
GF Value €9.81
! 6 Warning Signs
View Full Analysis

What is Concord Medical Services Holdings ROCE %?

Concord Medical Services Holdings FRA:C2C 51 ROCE % is -5.56% as of Dec. 2025. GuruFocus rates FRA:C2C with a GF Score™ of 51/100 and a GF Value™ of €9.81. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Concord Medical Services Holdings's annualized ROCE % for the quarter that ended in Dec. 2025 was -5.56%.

Concord Medical Services Holdings  (FRA:C2C) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Concord Medical Services Holdings ROCE % Related Terms

Concord Medical Services Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Concord Medical Services Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Medical Services Holdings ROCE % Chart

Concord Medical Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.31 -13.77 -8.43 -11.06 -4.62

Concord Medical Services Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.87 -12.55 -9.29 -4.22 -5.56
FRA:C2C
51GF Score
Concord Medical Services Holdings Ltd FRA:C2C
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Medical Services Holdings ROCE % Calculation

Concord Medical Services Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-26.8/( ( (882.292 - 278.78) + (793.879 - 236.976) )/ 2 )
=-26.8/( (603.512+556.903)/ 2 )
=-26.8/580.2075
=-4.62 %

Concord Medical Services Holdings's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-29.852/( ( (813.035 - 296.345) + (793.879 - 236.976) )/ 2 )
=-29.852/( ( 516.69 + 556.903 )/ 2 )
=-29.852/536.7965
=-5.56 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -5.56% mean?
Concord Medical Services Holdings (FRA:C2C) has a ROCE % of -5.56% as of Dec. 2025.
Is Concord Medical Services Holdings' ROCE % too high?
Concord Medical Services Holdings' current ROCE % is -5.56%. Overall, Concord Medical Services Holdings has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' ROCE % compare to CCEL and GBCS?
Concord Medical Services Holdings' ROCE % of -5.56% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Medical Services Holdings's current ROCE % is -5.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current ROCE % of -5.56%. The stock's GF Value™ is €9.81, compared to a current price of €6.25 — trading 36.3% below its estimated fair value. The current ROCE % is -5.56%. Concord Medical Services Holdings' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current ROCE % is -5.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued. The current stock price of €6.25 is trading 36.3% below its estimated GF Value™ of €9.81.

Key valuation signals for FRA:C2C:

  • ROCE %: -5.56%
  • GF Value™: €9.81 vs. price of €6.25 (36.3% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Medical Services Holdings Business Description

Other Exchanges CCM:USA
Address Hanwei Plaza Building, No. 7 Guanghua Road, Room A1-A5, 26th Floor, East Area, Chaoyang District, Beijing, CHN, 100020
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
51GF Score

Get the complete analysis for FRA:C2C

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.25
Price
€9.81
GF Value